OptiViVax Optimising a High Efficacy Plasmodium vivax Malaria Vaccine
- Coordinator
- Stichting Radboud Universitair Medisch Centrum, Netherlands
- Runs
- 1 June 2023 to 31 May 2028
- Status
- Running
- EU funding
- €3.8m
- Total cost
- €3.8m
- Partners
- 10 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080744
What the project is doing
In the project's own words, from its summary on CORDIS.
Plasmodium vivax is the most widespread human malaria with 2.5 billion people living at risk in South America, Oceania and Asia. The revised Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria, calling for a vaccine intervention to achieve 75% efficacy over two years, now equally weighted with P. falciparum. However, if this ambition is to be realised, new and innovative approaches are urgently required to accelerate next-generation vaccine research and development, whilst the few known candidate antigens need to undergo early-phase clinical assessment.
Here, we build on exciting breakthroughs in P. vivax vaccine research, recently pioneered in Europe, including new transgenic parasite technologies for functional assay development and production of a parasite clone that is safe for use in controlled human malaria infection (CHMI) clinical models. The Objectives of OptiViVax will now integrate ambitious multi-disciplinary scientific and clinical approaches around the parasite’s lifecycle and will use our increased knowledge of P. vivax immuno-biology to further develop next-generation vaccines with improved efficacy.
We will diversify the portfolio of new antigens ready for clinical testing by reverse vaccinology and diversify their delivery with new platforms and adjuvants developed using sustainable and improved GMP bio-manufacturing know-how. In parallel, the efficacy of known leading antigens will be benchmarked for the first time using innovative design of clinical studies and CHMI models making these lead candidate vaccines ready for future field trials.
Improved preclinical functional assays, using state-of-the-art transgenic parasite lines, will also allow for mechanisms of antibody-mediated protection to be deciphered. The availability of new functional assays and human challenge models will underpin the future framework for informed decision making by the clinical vaccine community, policy makers, funders and regulators.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Coordinator |
| Vaccine Formulation Institute(ch)ltd | Plan Les Ouates | Switzerland | Associatedpartner |
| Armauer Hansen Research Institute | Addis Ababa | ET | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| University College Cork - National University of Ireland, Cork | Cork | Ireland | Participant |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Participant |
| Novavax AB | Uppsala | Sweden | Participant |
| London School of Hygiene and Tropical Medicine Royal Charter | London | United Kingdom | Associatedpartner |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI